Terms: = Prostate cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Treatment
91 results:
1. Image-guided moderately hypofractionated radiotherapy for localized prostate cancer: a multicentric retrospective study (IPOPROMISE).
Ingrosso G; Ponti E; Francolini G; Caini S; Fondelli S; Santini R; Valeriani M; Rago L; Duroni G; Bruni A; Augurio A; Tramacere F; Trippa F; Russo D; Bottero M; Tamburo M; Parisi S; Borghesi S; Lancia A; Gomellini S; Scoccianti S; Stefanacci M; Vullo G; Statuto T; Miranda G; Santo B; Di Marzo A; Bellavita R; Vinciguerra A; Livi L; Aristei C; Bertini N; Orsatti C; Detti B
Radiol Med; 2024 Apr; 129(4):643-652. PubMed ID: 38369638
[TBL] [Abstract] [Full Text] [Related]
2. Integrated analysis identifies GABRB3 as a biomarker in prostate cancer.
Chen JY; Chang CF; Huang SP; Huang CY; Yu CC; Lin VC; Geng JH; Li CY; Lu TL; Bao BY
BMC Med Genomics; 2024 Jan; 17(1):41. PubMed ID: 38287309
[TBL] [Abstract] [Full Text] [Related]
3. Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis.
Shimomura T; Mori K; Yasue K; Matsukawa A; Fukuokaya W; Yanagisawa T; Hata K; Murakami M; Koike Y; Miki J; Yamada H; Kimura T
Int J Clin Oncol; 2024 Feb; 29(2):213-221. PubMed ID: 38103156
[TBL] [Abstract] [Full Text] [Related]
4. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K; Azad AA; Matsubara N; Carles J; Fay AP; De Giorgi U; Joung JY; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Ye D; Lin X; Healy CG; Di Santo N; Laird AD; Zohren F; Agarwal N
Nat Med; 2024 Jan; 30(1):257-264. PubMed ID: 38049622
[TBL] [Abstract] [Full Text] [Related]
5. treatment patterns and outcomes in older adults with castration-resistant prostate cancer: Analysis of an Australian real-world cohort.
Fernando M; Anton A; Weickhardt A; Azad AA; Uccellini A; Brown S; Wong S; Parente P; Shapiro J; Liow E; Torres J; Goh J; Parnis F; Steer C; Warren M; Gibbs P; Tran B
J Geriatr Oncol; 2023 Nov; 14(8):101621. PubMed ID: 37683368
[TBL] [Abstract] [Full Text] [Related]
6. A pilot study of an organised population-based testing programme for prostate cancer.
Alterbeck M; Thimansson E; Bengtsson J; Baubeta E; Zackrisson S; Bolejko A; Sandeman K; Carlsson S; Jiborn T; Bjartell A
BJU Int; 2024 Jan; 133(1):87-95. PubMed ID: 37523331
[TBL] [Abstract] [Full Text] [Related]
7. Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan.
Matsuyama H; Matsubara N; Kazama H; Seto T; Sunaga Y; Suzuki K
BMC Cancer; 2023 Jun; 23(1):538. PubMed ID: 37308888
[TBL] [Abstract] [Full Text] [Related]
8. Collecting duct carcinoma: Epidemiology, clinical characteristics and survival.
Panunzio A; Tappero S; Hohenhorst L; Cano Garcia C; Piccinelli M; Barletta F; Tian Z; Tafuri A; Briganti A; De Cobelli O; Chun FKH; Tilki D; Terrone C; Kapoor A; Saad F; Shariat SF; Cerruto MA; Antonelli A; Karakiewicz PI
Urol Oncol; 2023 Feb; 41(2):110.e7-110.e14. PubMed ID: 36456452
[TBL] [Abstract] [Full Text] [Related]
9. Cardiac Biomarkers and Geriatric Assessment in Metastatic Castrate-Resistant prostate cancer During Abiraterone Acetate Therapy - A Cardio-Oncology Study.
Wilk M; Waśko-Grabowska A; Skoneczna I; Szczylik C; Szmit S
Cancer Control; 2022; 29():10732748221140696. PubMed ID: 36447439
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.
Kazama H; Kawaguchi O; Seto T; Suzuki K; Matsuyama H; Matsubara N; Tajima Y; Fukao T
BMC Cancer; 2022 Apr; 22(1):470. PubMed ID: 35484517
[TBL] [Abstract] [Full Text] [Related]
11. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada.
Shayegan B; Wallis CJD; Hamilton RJ; Morgan SC; Cagiannos I; Basappa NS; Ferrario C; Gotto GT; Fernandes R; Roy S; Noonan KL; Niazi T; Hotte SJ; Saad F; Hew H; Park-Wyllie L; Chan KFY; Malone S
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):74-79. PubMed ID: 35197558
[TBL] [Abstract] [Full Text] [Related]
12. Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic prostate cancer.
Wallis CJD; Malone S; Cagiannos I; Morgan SC; Hamilton RJ; Basappa NS; Ferrario C; Gotto GT; Fernandes R; Niazi T; Noonan KL; Saad F; Hotte SJ; Hew H; Chan KFY; Wyllie LP; Shayegan B
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926988
[TBL] [Abstract] [Full Text] [Related]
13. Is tumour volume an independent predictor of outcome after radical prostatectomy for high-risk prostate cancer?
Raison N; Servian P; Patel A; Santhirasekaram A; Smith A; Yeung M; Lloyd J; Mannion E; Rockall A; Ahmed H; Winkler M
Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):282-286. PubMed ID: 34845306
[TBL] [Abstract] [Full Text] [Related]
14. A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
Payne H; Robinson A; Rappe B; Hilman S; De Giorgi U; Joniau S; Bordonaro R; Mallick S; Dourthe LM; Flores MM; Gumà J; Baron B; Duran A; Pranzo A; Serikoff A; Mott D; Herdman M; Pavesi M; De Santis M
Int J Cancer; 2022 Mar; 150(5):837-846. PubMed ID: 34648657
[TBL] [Abstract] [Full Text] [Related]
15. High rate of local control and cure at 10 years after treatment of prostate cancer with external beam radiotherapy and high-dose-rate brachytherapy: a single centre experience.
Hjälm-Eriksson M; Nilsson S; Brandberg Y; Johansson H; Lennernäs B; Lundell G; Castellanos E; Ullén A
Acta Oncol; 2021 Oct; 60(10):1301-1307. PubMed ID: 34498986
[TBL] [Abstract] [Full Text] [Related]
16. Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kaneko H; Tajima Y; Oya M
Jpn J Clin Oncol; 2021 Nov; 51(11):1656-1664. PubMed ID: 34350454
[TBL] [Abstract] [Full Text] [Related]
17. Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative.
Vince RA; Jiang R; Qi J; Tosoian JJ; Takele R; Feng FY; Linsell S; Johnson A; Shetty S; Hurley P; Miller DC; George A; Ghani K; Sun F; Seymore M; Dess RT; Jackson WC; Schipper M; Spratt DE; Morgan TM
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):677-683. PubMed ID: 34285350
[TBL] [Abstract] [Full Text] [Related]
18. Inflammatory factor-based prognostic risk stratification for patients with metastatic castration-resistant prostate cancer treated with docetaxel.
Shi X; Fan J; Pei X; Wang Y; Guo G; Yang T; Wang X; He D; Li L
Andrologia; 2021 Jul; 53(6):e14064. PubMed ID: 33900646
[TBL] [Abstract] [Full Text] [Related]
19. Biweekly DoceAqualip in mCRPC patients beyond 20 cycles: A case series.
Tiwari S; Bisaria A; Kaur H; Joshi N; Sejpal J; Khan MA
J Oncol Pharm Pract; 2021 Dec; 27(8):2030-2034. PubMed ID: 33853469
[TBL] [Abstract] [Full Text] [Related]
20. Active Surveillance for Incidental (cT1a/b) prostate cancer: Long-Term Outcomes of the Prospective Noninterventional HAROW Study.
Herden J; Schwarte A; Boedefeld EA; Weissbach L
Urol Int; 2021; 105(5-6):428-435. PubMed ID: 33517336
[TBL] [Abstract] [Full Text] [Related]
[Next]
